SAVITHA BALARAMAN, MD

New patient office or other outpatient visit, 60-74 minutes

Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes

Established patient office or other outpatient visit, 40-54 minutes

Leuprolide acetate (for depot suspension), 7.5 mg

Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l

Administration of chemotherapy into vein, 1 hour or less

Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes

Established patient office or other outpatient visit, 30-39 minutes

Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg

Injection, pegfilgrastim, excludes biosimilar, 0.5 mg

New patient office or other outpatient visit, 30-44 minutes

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes

Established patient office or other outpatient visit, 20-29 minutes

Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less

Administration of additional new drug or substance into vein, 1 hour or less

Influenza vaccine split virus, preservative free

Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes

Administration of additional new drug or substance into vein using push technique

Established patient office or other outpatient visit, 10-19 minutes

Telephone medical discussion with physician, 5-10 minutes

Injection, pembrolizumab, 1 mg

Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg

Injection of drug or substance into vein

Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes

Infusion into a vein for hydration, 31-60 minutes

Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle

Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less

Administration of chemotherapy into vein, each additional hour

Irrigation of implanted venous access drug delivery device

Injection, denosumab, 1 mg

Infusion into a vein for therapy, prevention, or diagnosis, each additional hour

Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion

Application of on-body injector for under skin injection

Injection of additional new drug or substance into vein

Injection of drug or substance under skin or into muscle

Infusion into a vein for hydration, each additional hour

Blood test, basic group of blood chemicals (calcium, ionized)

Bilirubin level, total

Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units

Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count

Blood creatinine level

Injection, leucovorin calcium, per 50 mg

Urea nitrogen level to assess kidney function, quantitative

Injection, carboplatin, 50 mg

Infusion, normal saline solution , 1000 cc

Injection, fluorouracil, 500 mg

Administration of influenza virus vaccine

Unclassified drugs

Injection, ferric carboxymaltose, 1 mg